The present disclosure relates to glycoproteins, particularly
monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-
glycan having the structure of Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2. The glycoengineered Fc region binds FcγRIIA or FcγRIIIA with a greater affinity, relative to comparable
monoclonal antibodies comprising the wild-type Fc region. The
monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a
disease, disorder, or infection where an enhanced
efficacy of
effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g.,
cancer, autoimmune, infectious
disease, and in enhancing the therapeutic
efficacy of therapeutic antibodies the effect of which is mediated by ADCC.